|
humans |
55 |
|
hepatocellular carcinoma |
50 |
|
medical sciences |
49 |
|
female |
42 |
|
male |
41 |
|
adult |
35 |
|
middle aged |
33 |
|
gastroenterology |
32 |
|
aged |
30 |
|
chronic hepatitis b |
30 |
|
hepatitis b virus |
29 |
|
liver transplantation |
28 |
|
hepatitis b |
27 |
|
cirrhosis |
25 |
|
adolescent |
23 |
|
nafld |
22 |
|
hbsag |
21 |
|
hbv |
21 |
|
fatty liver disease |
20 |
|
functional cure |
20 |
|
follow-up studies |
19 |
|
hepatitis b surface antigen |
19 |
|
prognosis |
19 |
|
hepatitis b virus - genetics |
18 |
|
nucleoside analogues |
18 |
|
obesity |
18 |
|
aged, 80 and over |
17 |
|
antiviral therapy |
17 |
|
chronic liver disease |
17 |
|
dna, viral - blood |
17 |
|
fibrosis |
17 |
|
liver stiffness |
17 |
|
mutation |
17 |
|
entecavir |
16 |
|
genotype |
16 |
|
lamivudine |
16 |
|
reverse transcriptase polymerase chain reaction |
16 |
|
transfection |
16 |
|
antiviral agents - therapeutic use |
15 |
|
covid-19 |
15 |
|
hcc |
15 |
|
hong kong - epidemiology |
15 |
|
antiviral |
14 |
|
antiviral agents - adverse effects - therapeutic use |
14 |
|
beta catenin |
14 |
|
biomarker |
14 |
|
cap |
14 |
|
epidemiology |
14 |
|
gastroenterology medical sciences |
14 |
|
liver cancer |
14 |
|
liver failure |
14 |
|
liver fibrosis |
14 |
|
metabolic syndrome |
14 |
|
prevalence |
14 |
|
recurrence |
14 |
|
risk factors |
14 |
|
surgery |
14 |
|
tenofovir |
14 |
|
treatment outcome |
14 |
|
alanine transaminase - blood |
13 |
|
hepatitis c |
13 |
|
liver biopsy |
13 |
|
vaccination |
13 |
|
vcte |
13 |
|
decompensation |
12 |
|
disease progression |
12 |
|
dna, viral - analysis |
12 |
|
hepatitis b e antigens - blood |
12 |
|
hong kong |
12 |
|
intercellular communication |
12 |
|
lamivudine - therapeutic use |
12 |
|
mortality |
12 |
|
promoter regions, genetic - genetics |
12 |
|
retrospective studies |
12 |
|
reverse transcriptase inhibitors - therapeutic use |
12 |
|
seroclearance |
12 |
|
time factors |
12 |
|
tlr7 agonist |
12 |
|
virus replication |
12 |
|
acute flare |
11 |
|
anti-hbs |
11 |
|
biomarkers |
11 |
|
carcinoma, hepatocellular - etiology - genetics - metabolism |
11 |
|
carcinoma, hepatocellular - virology |
11 |
|
cell line, tumor |
11 |
|
child |
11 |
|
controlled attenuation parameter |
11 |
|
cyclin d1 - biosynthesis - genetics |
11 |
|
cytoskeletal proteins - genetics |
11 |
|
elasticity imaging techniques |
11 |
|
extracellular vesicles |
11 |
|
gastric cancer |
11 |
|
hbv dna |
11 |
|
hcv |
11 |
|
helicobacter pylori |
11 |
|
hepatitis b core-related antigen |
11 |
|
hepatitis b, chronic - complications |
11 |
|
liver |
11 |
|
liver cirrhosis - complications - diagnosis |
11 |
|
liver neoplasms - virology |
11 |
|
long covid |
11 |
|
longitudinal studies |
11 |
|
mafld (metabolic associated fatty liver disease) |
11 |
|
meld |
11 |
|
natural history |
11 |
|
nidogen 1 |
11 |
|
non-alcoholic fatty liver disease |
11 |
|
overweight |
11 |
|
peptidyl-prolyl-isomerase |
11 |
|
peptidylprolyl isomerase - biosynthesis - genetics |
11 |
|
pin1 |
11 |
|
population based study |
11 |
|
post-covid-19 syndrome |
11 |
|
predictive value of tests |
11 |
|
prevention |
11 |
|
pre‐metastatic niche |
11 |
|
resistance |
11 |
|
sars-cov-2 infection |
11 |
|
trans-activators - genetics |
11 |
|
tumor microenvironment |
11 |
|
tumor necrosis factor receptor 1 |
11 |
|
β-catenin |
11 |
|
carcinoma, hepatocellular - etiology |
10 |
|
child, preschool |
10 |
|
china |
10 |
|
drug therapy, combination |
10 |
|
hbcrag |
10 |
|
hepatitis b antibodies - blood |
10 |
|
hepatitis c virus |
10 |
|
infant |
10 |
|
liver - pathology - virology |
10 |
|
liver cirrhosis - etiology |
10 |
|
m2bpgi |
10 |
|
models, biological |
10 |
|
neutralizing antibody |
10 |
|
pharmacokinetics |
10 |
|
promoter regions, genetic |
10 |
|
proteomics |
10 |
|
surface antigen |
10 |
|
survival analysis |
10 |
|
adefovir |
9 |
|
age factors |
9 |
|
apoptosis |
9 |
|
asian continental ancestry group - statistics & numerical data |
9 |
|
carcinoma, hepatocellular - ethnology - pathology - virology |
9 |
|
carrier state |
9 |
|
cccdna |
9 |
|
chronic hepatitis b virus |
9 |
|
chronic viral hepatitis |
9 |
|
dna methylation |
9 |
|
endocrinology |
9 |
|
flare |
9 |
|
genetic predisposition to disease |
9 |
|
hav |
9 |
|
hbeag |
9 |
|
hepatitis b - complications |
9 |
|
hepatitis b surface antigens - immunology |
9 |
|
hepatitis b vaccination |
9 |
|
hepatitis b virus - genetics - immunology - isolation & purification |
9 |
|
hepatitis b, chronic - pathology |
9 |
|
hev |
9 |
|
immigration |
9 |
|
liver cirrhosis - pathology - virology |
9 |
|
liver neoplasms - etiology |
9 |
|
microrna |
9 |
|
nash |
9 |
|
non-viral liver disease |
9 |
|
nucleoside analogue |
9 |
|
pre-s deletions |
9 |
|
prospective studies |
9 |
|
reproducibility of results |
9 |
|
telbivudine |
9 |
|
transient elastography |
9 |
|
tumorigenesis |
9 |
|
viral hepatitis |
9 |
|
alanine transaminase - metabolism |
8 |
|
allergology and immunology |
8 |
|
carcinoma, hepatocellular - surgery - virology |
8 |
|
case-control studies |
8 |
|
core protein allosteric modulator |
8 |
|
delns1-ncov-rbd laiv |
8 |
|
dialysis |
8 |
|
elasticity imaging techniques - methods |
8 |
|
etv |
8 |
|
fibroscan |
8 |
|
guanine - adverse effects - analogs and derivatives - therapeutic use |
8 |
|
hepatitis |
8 |
|
hepatitis b core antigen |
8 |
|
hepatitis b e antigens - metabolism |
8 |
|
hepatitis b virus - genetics - immunology |
8 |
|
hepatitis b, chronic - complications - diagnosis |
8 |
|
hepatitis b, chronic - complications - diagnosis - drug therapy - surgery |
8 |
|
hepatitis b, chronic - drug therapy - virology |
8 |
|
hla‐dp |
8 |
|
ifn‐γ pathway |
8 |
|
immune response |
8 |
|
inflammation |
8 |
|
intradermal |
8 |
|
intranasal |
8 |
|
liver - pathology |
8 |
|
liver cirrhosis - surgery - virology |
8 |
|
liver disease |
8 |
|
liver failure - pathology - virology |
8 |
|
longitudinal |
8 |
|
nephrotoxicity |
8 |
|
nucleos(t)ide analogue |
8 |
|
outcomes |
8 |
|
phase-1 |
8 |
|
promoter regions (genetics) - genetics |
8 |
|
protein precursors - genetics |
8 |
|
questionnaires |
8 |
|
serology |
8 |
|
survival rate |
8 |
|
transcription, genetic |
8 |
|
transplantation |
8 |
|
accuracy |
7 |
|
acute disease |
7 |
|
advanced cirrhosis |
7 |
|
alanine aminotransferase blood level |
7 |
|
alkaline phosphatase |
7 |
|
animals |
7 |
|
anti-ulcer agents - therapeutic use |
7 |
|
asian continental ancestry group - genetics |
7 |
|
biliary |
7 |
|
body mass index |
7 |
|
breath tests |
7 |
|
china - ethnology |
7 |
|
cholangiogram |
7 |
|
covalently closed circular dna |
7 |
|
diabetes mellitus |
7 |
|
diagnostic test accuracy study |
7 |
|
disease severity |
7 |
|
drug response |
7 |
|
dyspepsia |
7 |
|
e-cadherin |
7 |
|
elastography |
7 |
|
hepatitis b - drug therapy - prevention & control - surgery |
7 |
|
hepatitis b antibodies |
7 |
|
hepatitis b core antigens - genetics |
7 |
|
hepatitis b surface antigens - blood - immunology |
7 |
|
hepatitis b virus - classification - genetics |
7 |
|
hepatitis b virus - drug effects - genetics |
7 |
|
hepatitis b virus - physiology |
7 |
|
hepatitis b virus infection |
7 |
|
hepatitis b, chronic - blood - drug therapy - virology |
7 |
|
hepatitis b, chronic - enzymology - pathology |
7 |
|
hepatorenal syndrome |
7 |
|
interferon-alpha - therapeutic use |
7 |
|
itraq |
7 |
|
ketamine |
7 |
|
lamivudine - administration and dosage |
7 |
|
liver - chemistry - pathology |
7 |
|
liver cirrhosis - enzymology - pathology |
7 |
|
mafld |
7 |
|
magnetic resonance cholangiography |
7 |
|
metabolic |
7 |
|
mutation - genetics |
7 |
|
noncardiac chest pain |
7 |
|
nucleotide analogue |
7 |
|
occult hepatitis b |
7 |
|
placebos |
7 |
|
polymorphism, genetic |
7 |
|
proportional hazards models |
7 |
|
recombinant proteins |
7 |
|
response to therapy |
7 |
|
risk factor |
7 |
|
safety |
7 |
|
sensitivity and specificity |
7 |
|
statistics, nonparametric |
7 |
|
substance abuse |
7 |
|
treatment |
7 |
|
viral core proteins - genetics |
7 |
|
viral load |
7 |
|
viral suppression |
7 |
|
young adult |
7 |
|
adverse outcome |
6 |
|
age |
6 |
|
alanine aminotransferase |
6 |
|
alpha-fetoproteins - analysis |
6 |
|
anti-bacterial agents - pharmacology - therapeutic use |
6 |
|
anti-hbc |
6 |
|
antibody to hepatitis b surface antigen |
6 |
|
antineoplastic agents, hormonal - administration & dosage |
6 |
|
asia |
6 |
|
asian continental ancestry group |
6 |
|
aspartate aminotransferase |
6 |
|
base sequence |
6 |
|
blood donors - statistics and numerical data |
6 |
|
cancer |
6 |
|
carcinoma, hepatocellular - blood - metabolism |
6 |
|
carcinoma, hepatocellular - diagnosis - epidemiology |
6 |
|
carcinoma, hepatocellular - drug therapy - mortality |
6 |
|
carcinoma, hepatocellular - epidemiology - genetics - virology |
6 |
|
carcinoma, hepatocellular - etiology - pathology - surgery - virology |
6 |
|
carrier state - epidemiology - pathology |
6 |
|
chi-square distribution |
6 |
|
cholangiopancreatography, endoscopic retrograde |
6 |
|
chromosome 8p |
6 |
|
cigarette smoking |
6 |
|
circular dna |
6 |
|
cure |
6 |
|
data mining |
6 |
|
diagnosis |
6 |
|
dkk1 |
6 |
|
drug resistance |
6 |
|
drug resistance, viral |
6 |
|
drug resistance, viral - genetics |
6 |
|
enhancer elements (genetics) - genetics |
6 |
|
fatty liver |
6 |
|
feedback signaling |
6 |
|
full-length genome sequencing |
6 |
|
gene expression regulation, neoplastic |
6 |
|
gene silencing |
6 |
|
genetic association |
6 |
|
genotype 1 |
6 |
|
genotype 6 |
6 |
|
gitr |
6 |
|
guanine - analogs and derivatives - therapeutic use |
6 |
|
hbeag seroconversion |
6 |
|
hepacivirus - classification - genetics - pathogenicity |
6 |
|
hepacivirus - genetics |
6 |
|
hepatic encephalopathy - surgery |
6 |
|
hepaticolenticular degeneration |
6 |
|
hepatitis b - prevention & control - surgery |
6 |
|
hepatitis b core‐related antigen |
6 |
|
hepatitis b serum markers |
6 |
|
hepatitis b surface antigens - analysis - blood |
6 |
|
hepatitis b virus - drug effects |
6 |
|
hepatitis b virus - isolation and purification |
6 |
|
hepatitis b(e) antigen |
6 |
|
hepatitis b, chronic - blood - complications - genetics |
6 |
|
hepatitis b, chronic - blood - complications - immunology - pathology - virology |
6 |
|
hepatitis b, chronic - complications - drug therapy |
6 |
|
hepatitis b, chronic - complications - virology |
6 |
|
hepatitis b, chronic - drug therapy - enzymology - immunology |
6 |
|
hepatitis b, chronic - epidemiology - pathology |
6 |
|
hepatitis b, chronic - ethnology - immunology - pathology |
6 |
|
hepatitis b, chronic - mortality - surgery |
6 |
|
hepatitis c, chronic - complications - metabolism - virology |
6 |
|
hepatitis c, chronic - drug therapy - virology |
6 |
|
host-pathogen interactions |
6 |
|
hs-hbsag |
6 |
|
immune exhaustion |
6 |
|
incidence |
6 |
|
intercellular signaling peptides and proteins - blood - metabolism |
6 |
|
interleukin‐27 |
6 |
|
intrahepatic hbv dna |
6 |
|
kinetics |
6 |
|
lamivudine - adverse effects - therapeutic use |
6 |
|
lamivudine - pharmacology - therapeutic use |
6 |
|
liver carcinogenesis |
6 |
|
liver cirrhosis - ethnology - pathology - virology |
6 |
|
liver neoplasms - blood - metabolism |
6 |
|
liver neoplasms - diagnosis - epidemiology |
6 |
|
liver neoplasms - drug therapy - mortality |
6 |
|
liver neoplasms - epidemiology - genetics - virology |
6 |
|
liver neoplasms - ethnology - pathology - virology |
6 |
|
liver neoplasms - etiology - pathology - surgery - virology |
6 |
|
liver transplantation - mortality |
6 |
|
mac-2 binding protein glycosylation isomer |
6 |
|
mass screening - methods |
6 |
|
mice |
6 |
|
na therapy |
6 |
|
neoplasm staging |
6 |
|
octreotide - administration & dosage |
6 |
|
omeprazole - pharmacology - therapeutic use |
6 |
|
pd-1 |
6 |
|
platelet ratio index |
6 |
|
polymerase chain reaction - methods |
6 |
|
polymorphism, single nucleotide |
6 |
|
prediction |
6 |
|
primary biliary cholangitis |
6 |
|
quality of life |
6 |
|
quasispecies |
6 |
|
questionnaires - standards |
6 |
|
regulatory t cells |
6 |
|
ribavirin |
6 |
|
rna interference |
6 |
|
rna-directed dna polymerase - genetics |
6 |
|
roc curve |
6 |
|
seroepidemiologic studies |
6 |
|
severity of illness index |
6 |
|
sex factors |
6 |
|
small extracellular vesicles |
6 |
|
spontaneous hbeag seroconversion |
6 |
|
t regulatory cells |
6 |
|
tenofovir hbsag surface antigen nucleoside analogue nucleotide analogue tdf |
6 |
|
tricuspid annuloplasty |
6 |
|
tumor markers, biological - blood - metabolism |
6 |
|
ursodeoxycholic acid |
6 |
|
virology |
6 |
|
virus dna |
6 |
|
von willebrand factor |
6 |
|
wfa + -m2bp |
6 |
|
wnt |
6 |
|
acute-on-chronic liver failure |
5 |
|
adenine - analogs and derivatives - therapeutic use |
5 |
|
alanine transaminase - analysis |
5 |
|
alkaline phosphatase - blood |
5 |
|
alt |
5 |
|
amoxicillin - pharmacology - therapeutic use |
5 |
|
anaemia |
5 |
|
anti-inflammatory agents, non-steroidal - adverse effects |
5 |
|
antineoplastic agents - administration & dosage |
5 |
|
antiviral agents - administration and dosage - therapeutic use |
5 |
|
aspartate aminotransferases - blood |
5 |
|
aspirin |
5 |
|
berberine |
5 |
|
besifovir |
5 |
|
biliary tract diseases - chemically induced - diagnosis |
5 |
|
bilirubin - blood |
5 |
|
biological markers - blood |
5 |
|
biopsy |
5 |
|
blotting, western |
5 |
|
capsid inhibitor |
5 |
|
carcinoembryonic antigen |
5 |
|
carcinoma, hepatocellular - diagnosis - pathology |
5 |
|
ceruloplasmin - metabolism |
5 |
|
chinese |
5 |
|
copper/urine |
5 |
|
coptidis rhizoma aqueous extract |
5 |
|
core antigen |
5 |
|
core protein |
5 |
|
cross-sectional studies |
5 |
|
customized therapies |
5 |
|
cytokines |
5 |
|
deep sequencing |
5 |
|
deleterious mutations |
5 |
|
dna mutational analysis - methods |
5 |
|
dna, circular - analysis - isolation & purification |
5 |
|
dna, viral - analysis - isolation & purification |
5 |
|
dna, viral - genetics |
5 |
|
dna-directed dna polymerase - genetics |
5 |
|
dose-response relationship, drug |
5 |
|
drugs, chinese herbal - adverse effects |
5 |
|
dyslipidemia |
5 |
|
efficacy |
5 |
|
elbasvir |
5 |
|
emergencies |
5 |
|
enzyme inhibitors - therapeutic use |
5 |
|
freezing |
5 |
|
gamma-glutamyltransferase - blood |
5 |
|
gastroesophageal reflux |
5 |
|
gene deletion |
5 |
|
gene expression regulation, viral |
5 |
|
genipin |
5 |
|
globulins - analysis |
5 |
|
grazoprevir |
5 |
|
guanine - administration and dosage - analogs and derivatives - therapeutic use |
5 |
|
h(+)-k(+)-exchanging atpase - antagonists & inhibitors |
5 |
|
hbsag level |
5 |
|
hbsag seroclearance |
5 |
|
hbv // chb |
5 |
|
hbv reactivation |
5 |
|
hbx |
5 |
|
hbx protein |
5 |
|
helicobacter infections - drug therapy - metabolism |
5 |
|
hepatitic decompensation |
5 |
|
hepatitis b - drug therapy - genetics - physiopathology - virology |
5 |
|
hepatitis b core antigens - genetics - immunology |
5 |
|
hepatitis b e antigen |
5 |
|
hepatitis b e antigen seroconversion |
5 |
|
hepatitis b e antigens - biosynthesis - genetics - immunology |
5 |
|
hepatitis b surface antigens - blood |
5 |
|
hepatitis b surface antigens - blood - chemistry |
5 |
|
hepatitis b surface antigens - genetics |
5 |
|
hepatitis b surface antigens - metabolism |
5 |
|
hepatitis b virus - chemistry - classification - genetics |
5 |
|
hepatitis b virus - drug effects - enzymology - genetics |
5 |
|
hepatitis b virus - genetics - immunology - isolation and purification |
5 |
|
hepatitis b virus - genetics - isolation and purification |
5 |
|
hepatitis b virus dna rebound |
5 |
|
hepatitis b virus replication |
5 |
|
hepatitis b, chronic - blood - drug therapy |
5 |
|
hepatitis b, chronic - blood - pathology - virology |
5 |
|
hepatitis b, chronic - complications - genetics - virology |
5 |
|
hepatitis b, chronic - complications - mortality - pathology |
5 |
|
hepatitis b, chronic - drug therapy |
5 |
|
hepatitis b, chronic - epidemiology - physiopathology - virology |
5 |
|
hepatitis b, chronic - genetics - immunology - virology |
5 |
|
hepatitis b, chronic - surgery |
5 |
|
hepatolenticular degeneration - complications - diagnosis - drug therapy - genetics - metabolism |
5 |
|
herbal medicine |
5 |
|
immunoenzyme techniques |
5 |
|
immunomodulator |
5 |
|
inhalant abuse - complications |
5 |
|
interferon-gamma - biosynthesis - immunology |
5 |
|
interleukin-10 - immunology |
5 |
|
interleukin-2 - immunology |
5 |
|
interleukin-4 - immunology |
5 |
|
interleukin-5 - immunology |
5 |
|
intracellular signaling peptides and proteins |
5 |
|
intrahepatic hepatitis b virus dna |
5 |
|
ire1α |
5 |
|
ketamine - administration and dosage - adverse effects |
5 |
|
lamivudine - administration & dosage - therapeutic use |
5 |
|
linearized hbsag |
5 |
|
liver - metabolism |
5 |
|
liver - virology |
5 |
|
liver biochemistry |
5 |
|
liver cirrhosis - diagnosis |
5 |
|
liver diseases - etiology |
5 |
|
liver histology |
5 |
|
liver steatosis |
5 |
|
lymphocyte activation |
5 |
|
medical sciences - oncology |
5 |
|
medical sciences - urology and nephrology |
5 |
|
medicine, chinese traditional - adverse effects |
5 |
|
mir-21 |
5 |
|
mir-23a |
5 |
|
multivariate analysis |
5 |
|
mutant |
5 |
|
myopathy |
5 |
|
nf-κb |
5 |
|
nucleocapsid |
5 |
|
nucleosides - pharmacology - therapeutic use |
5 |
|
obese mice |
5 |
|
occult hepatitis b infection |
5 |
|
ofloxacin - pharmacology - therapeutic use |
5 |
|
peptic ulcer - chemically induced - microbiology - prevention & control |
5 |
|
polyethylene glycols - therapeutic use |
5 |
|
practice guidelines as topic |
5 |
|
precore mutation |
5 |
|
promoter regions (genetics) |
5 |
|
prophylaxis |
5 |
|
protein stability |
5 |
|
pyrazoles - pharmacology |
5 |
|
pyrimidinones - pharmacology - therapeutic use |
5 |
|
quantitative |
5 |
|
response elements |
5 |
|
reverse transcriptase inhibitors - administration & dosage - therapeutic use |
5 |
|
ribavirin - therapeutic use |
5 |
|
risk assessment |
5 |
|
rna, messenger - analysis - isolation & purification |
5 |
|
rna, viral - analysis - isolation & purification |
5 |
|
s-loss |
5 |
|
serologic tests |
5 |
|
severe hepatitis b exacerbation |
5 |
|
sex distribution |
5 |
|
single polynucleotide polymorphisms |
5 |
|
sirt1 |
5 |
|
sirtuin |
5 |
|
specimen handling - methods |
5 |
|
statins |
5 |
|
stopping |
5 |
|
sulfonamides - pharmacology |
5 |
|
surgery medical sciences |
5 |
|
sustained virologic response |
5 |
|
t helper response |
5 |
|
targeted sequencing |
5 |
|
th1 cells - immunology |
5 |
|
th2 cells - immunology |
5 |
|
therapeutic vaccine |
5 |
|
transcription |
5 |
|
translation |
5 |
|
treatment guidelines |
5 |
|
tumor |
5 |
|
tumor cells, cultured |
5 |
|
tumor markers, biological - blood |
5 |
|
tumour-associated macrophage |
5 |
|
type 2 |
5 |
|
urologic diseases - chemically induced |
5 |
|
varices |
5 |
|
viraemia |
5 |
|
viremia |
5 |
|
week 12 |
5 |
|
week 24 |
5 |
|
ymdd mutation |
5 |
|
acridine orange |
4 |
|
actins - genetics |
4 |
|
acute liver injury |
4 |
|
adenine - analogs & derivatives - therapeutic use |
4 |
|
adenocarcinoma - blood supply - genetics - pathology - therapy |
4 |
|
adenocarcinoma - drug therapy - enzymology - genetics |
4 |
|
adenocarcinoma - metabolism - pathology |
4 |
|
adenocarcinoma - pathology |
4 |
|
adenoma - complications |
4 |
|
adjuvant |
4 |
|
administration, oral |
4 |
|
adverse effects |
4 |
|
age distribution |
4 |
|
age of onset |
4 |
|
akt kinase/protein kinase b |
4 |
|
alcoholic liver disease |
4 |
|
alcoholic liver injury |
4 |
|
alpha catenin |
4 |
|
amino acid motifs - drug effects - genetics |
4 |
|
analysis of variance |
4 |
|
anti-hepatitis b core total antibodies |
4 |
|
anti-hiv agents - therapeutic use |
4 |
|
anti-infective agents - pharmacology - therapeutic use |
4 |
|
anti-inflammatory agents, non-steroidal - pharmacology |
4 |
|
anti-ulcer agents - pharmacology - therapeutic use |
4 |
|
antisense oligonucleotide |
4 |
|
antiviral agents - pharmacology - therapeutic use |
4 |
|
antiviral treatment |
4 |
|
apoptosis - drug effects |
4 |
|
apoptosis - genetics |
4 |
|
as-apex |
4 |
|
asian |
4 |
|
asian continental ancestry group - ethnology |
4 |
|
aspartic acid - drug effects - genetics |
4 |
|
aspirin - pharmacology |
4 |
|
b cell depletion |
4 |
|
bacteroides |
4 |
|
bile acid |
4 |
|
biopsy - instrumentation - methods |
4 |
|
biopsy - methods |
4 |
|
bismuth |
4 |
|
blood - virology |
4 |
|
blood transfusion - adverse effects |
4 |
|
breast feeding |
4 |
|
cadherins - blood |
4 |
|
cadherins - metabolism |
4 |
|
carbocyanines |
4 |
|
carbon isotopes - diagnostic use |
4 |
|
carcinogenesis |
4 |
|
carcinoma, hepatocellular - blood - complications - genetics |
4 |
|
carcinoma, hepatocellular - diagnosis - virology |
4 |
|
carcinoma, hepatocellular - mortality - pathology - therapy |
4 |
|
carnitine |
4 |
|
carrier proteins - blood - genetics |
4 |
|
carvedilol |
4 |
|
case report |
4 |
|
case series |
4 |
|
caspase |
4 |
|
caspases - metabolism |
4 |
|
catenin |
4 |
|
cell division - genetics |
4 |
|
chemoembolization, therapeutic - methods |
4 |
|
cholangiopancreatography, endoscopic retrograde - methods - mortality |
4 |
|
cholangitis - mortality - therapy |
4 |
|
chronic hbv infection |
4 |
|
chronic kidney disease |
4 |
|
cisplatin - administration & dosage |
4 |
|
clarithromycin - pharmacology - therapeutic use |
4 |
|
codon |
4 |
|
cohort studies |
4 |
|
colon cancer |
4 |
|
colonic neoplasms - drug therapy - enzymology - genetics |
4 |
|
colonic neoplasms - drug therapy - metabolism |
4 |
|
colonic neoplasms - genetics - metabolism - pathology |
4 |
|
colorectal neoplasms - complications |
4 |
|
complement c4 - metabolism |
4 |
|
complications of hbv reactivation |
4 |
|
contrast media - administration & dosage |
4 |
|
convalescence |
4 |
|
core promoter mutation |
4 |
|
core-promoter mutation |
4 |
|
coronary artery disease - complications |
4 |
|
cpams |
4 |
|
cpg islands |
4 |
|
cpsh |
4 |
|
cyclooxygenase |
4 |
|
cyclooxygenase 2 - chemistry - metabolism |
4 |
|
cyclooxygenase 2 inhibitors - pharmacology |
4 |
|
cyclooxygenase inhibitors - pharmacology |
4 |
|
cyclooxygenase-2 inhibitor sc236 |
4 |
|
cytochrome c |
4 |
|
cytochromes c - metabolism |
4 |
|
cytoskeletal proteins - metabolism |
4 |
|
deoxycytosine nucleotides |
4 |
|
direct acting antiviral |
4 |
|
dna methylation - immunology |
4 |
|
dna polymerase inhibitor |
4 |
|
dna, antisense - genetics |
4 |
|
dna, circular - analysis |
4 |
|
dna, circular - blood - drug effects |
4 |
|
dna, viral - blood - drug effects |
4 |
|
dna, viral - blood - isolation & purification |
4 |
|
dna, viral - genetics - isolation and purification |
4 |
|
dna-binding proteins - antagonists & inhibitors - genetics - metabolism |
4 |
|
dose-response relationship, immunologic |
4 |
|
down-regulation |
4 |
|
drug interaction |
4 |
|
drug resistance, multiple, viral - genetics |
4 |
|
drug-resistant mutations |
4 |
|
dyspepsia - pathology |
4 |
|
elasticity |
4 |
|
endoscopy, digestive system - instrumentation |
4 |
|
entry inhibitor |
4 |
|
enzyme activation |
4 |
|
enzyme-linked immunosorbent assay |
4 |
|
enzyme-linked immunosorbent assay - methods |
4 |
|
equipment reuse |
4 |
|
estrogen |
4 |
|
extrahepatic manifestation of hbv |
4 |
|
fanconi syndrome |
4 |
|
finite |
4 |
|
gastric carcinoma |
4 |
|
gastritis/genetics - immunology/prevention & control |
4 |
|
gender difference |
4 |
|
gene expression regulation - drug effects |
4 |
|
gene products, pol - genetics |
4 |
|
genome editing |
4 |
|
genotypes |
4 |
|
global elimination |
4 |
|
granulocytic‐myeloid‐derived suppressor cell‐like population |
4 |
|
guanine - analogs & derivatives - therapeutic use |
4 |
|
gut microbiota |
4 |
|
haplotypes |
4 |
|
hbv array |
4 |
|
hbv infection |
4 |
|
hbv rna |
4 |
|
hbv transcription |
4 |
|
health status indicators |
4 |
|
health surveys |
4 |
|
health-related quality of life |
4 |
|
helicobacter infections - drug therapy - pathology |
4 |
|
helicobacter infections/genetics - immunology/microbiology |
4 |
|
hepatic artery |
4 |
|
hepatitis b - drug therapy - genetics |
4 |
|
hepatitis b - drug therapy - genetics - virology |
4 |
|
hepatitis b - drug therapy - virology |
4 |
|
hepatitis b - immunology - prevention & control |
4 |
|
hepatitis b - pathology |
4 |
|
hepatitis b - transmission |
4 |
|
hepatitis b - virology |
4 |
|
hepatitis b antibodies - blood - immunology |
4 |
|
hepatitis b core antigens - blood |
4 |
|
hepatitis b core antigens - metabolism |
4 |
|
hepatitis b core protein |
4 |
|
hepatitis b e antigen (hbeag) |
4 |
|
hepatitis b genotype |
4 |
|
hepatitis b surface antigens |
4 |
|
hepatitis b surface antigens - blood - metabolism |
4 |
|
hepatitis b vaccines - administration & dosage - immunology |
4 |
|
hepatitis b virus (hbv) dna |
4 |
|
hepatitis b virus - chemistry |
4 |
|
hepatitis b virus - classification - genetics - isolation & purification - pathogenicity |
4 |
|
hepatitis b virus - classification - genetics - isolation and purification |
4 |
|
hepatitis b virus - genetics - isolation & purification |
4 |
|
hepatitis b virus rna |
4 |
|
hepatitis b, chronic - blood - drug therapy - genetics |
4 |
|
hepatitis b, chronic - blood - drug therapy - immunology |
4 |
|
hepatitis b, chronic - classification - diagnosis |
4 |
|
hepatitis b, chronic - complications - diagnosis - drug therapy - mortality |
4 |
|
hepatitis b, chronic - complications - drug therapy - ethnology |
4 |
|
hepatitis b, chronic - complications - epidemiology |
4 |
|
hepatitis b, chronic - complications - ethnology - therapy |
4 |
|
hepatitis b, chronic - diagnosis |
4 |
|
hepatitis b, chronic - drug therapy - ethnology - pathology |
4 |
|
hepatitis b, chronic - epidemiology |
4 |
|
hepatitis b, chronic - etiology |
4 |
|
hepatitis b, chronic - genetics |
4 |
|
hepatitis b, chronic - genetics - metabolism - pathology |
4 |
|
hepatitis b, chronic - metabolism |
4 |
|
hepatitis b, chronic - metabolism - physiopathology |
4 |
|
hepatitis b, chronic - pathology - physiopathology |
4 |
|
hepatitis b, chronic - physiopathology |
4 |
|
hepatitis b, chronic - physiopathology - virology |
4 |
|
hepatitis b, chronic - psychology |
4 |
|
hepatitis c, chronic - epidemiology |
4 |
|
hepatocarcinogenesis |
4 |
|
hepatotoxicity |
4 |
|
high mortality of acute pancreatitis |
4 |
|
histology |
4 |
|
histone acetylation |
4 |
|
hq-hbsag |
4 |
|
hsct |
4 |
|
human telomerase reverse transcriptase |
4 |
|
hypertension, portal - complications - surgery |
4 |
|
ibrutinib |
4 |
|
ici |
4 |
|
ifnar1 promoter polymorphisms |
4 |
|
ifnβ |
4 |
|
immunization schedule |
4 |
|
immunization, secondary |
4 |
|
immunogenicity |
4 |
|
immunohistochemistry |
4 |
|
immunologic memory |
4 |
|
immunomodulation |
4 |
|
indomethacin |
4 |
|
indomethacin - pharmacology |
4 |
|
inhibitor of apoptosis proteins |
4 |
|
injections, intra-arterial - methods |
4 |
|
integrated dna |
4 |
|
interferon regulatory factor-1 - metabolism |
4 |
|
interferon regulatory factor-1 - physiology |
4 |
|
interferon-beta - metabolism - pharmacology |
4 |
|
interleukin-1 receptor type 1 knockout mice |
4 |
|
interleukin-1b |
4 |
|
interleukin-1beta/genetics - immunology/metabolism |
4 |
|
interleukin-1β |
4 |
|
intestinal metaplasia |
4 |
|
iodized oil - administration & dosage |
4 |
|
ip-10 |
4 |
|
isoleucine - genetics |
4 |
|
kidney |
4 |
|
kidney diseases - complications - surgery |
4 |
|
kidney transplantation |
4 |
|
kidney transplantation - adverse effects - mortality |
4 |
|
lactic acidosis |
4 |
|
lamivudine - administration & dosage |
4 |
|
lb80380 |
4 |
|
limit of detection |
4 |
|
linkage disequilibrium |
4 |
|
liver cirrhosis - diagnosis - epidemiology - virology |
4 |
|
liver cirrhosis - genetics |
4 |
|
liver cirrhosis - pathology |
4 |
|
liver cirrhosis - pathology - physiopathology |
4 |
|
liver cirrhosis - physiopathology - virology |
4 |
|
liver cirrhosis - virology |
4 |
|
liver function tests |
4 |
|
liver neoplasms - blood - complications - genetics |
4 |
|
liver neoplasms - diagnosis - virology |
4 |
|
liver neoplasms - mortality - pathology - therapy |
4 |
|
liver transplant |
4 |
|
logistic models |
4 |
|
luciferases - metabolism |
4 |
|
luminescent measurements - methods |
4 |
|
macrophage migration-inhibitory factor |
4 |
|
macrophage migration-inhibitory factors - blood |
4 |
|
mannose-binding lectin - blood - genetics - metabolism |
4 |
|
methionine - drug effects - genetics |
4 |
|
metronidazole - pharmacology - therapeutic use |
4 |
|
mice, inbred balb c |
4 |
|
mice, nude |
4 |
|
microbiota |
4 |
|
microtubule-associated proteins - antagonists & inhibitors - biosynthesis - genetics |
4 |
|
mitogen-activated protein kinases - metabolism |
4 |
|
molecular sequence data |
4 |
|
muscle toxicity |
4 |
|
mutagenesis, site-directed |
4 |
|
mutation, missense - genetics |
4 |
|
nadolol |
4 |
|
necroinflammation |
4 |
|
necrosis - pathology |
4 |
|
neoadjuvant |
4 |
|
neoplasm proteins |
4 |
|
neoplasm proteins - genetics - metabolism |
4 |
|
neoplasm proteins - genetics - physiology |
4 |
|
neoplasm recurrence, local - blood |
4 |
|
neovascularization, pathologic - genetics - therapy |
4 |
|
nirmatrelvir/ritonavir |
4 |
|
nitric oxide |
4 |
|
noninvasive |
4 |
|
nonsteroidal antiinflammatory drugs |
4 |
|
novel therapy |
4 |
|
nsbb |
4 |
|
nucleos(t)ide analogs |
4 |
|
nucleoside analog |
4 |
|
nucleoside/ nucleotide analogue |
4 |
|
nucleotide analog |
4 |
|
oligonucleotide array sequence analysis - methods |
4 |
|
oral therapy |
4 |
|
osteomalacia |
4 |
|
pancreatitis - diagnosis - etiology |
4 |
|
peripheral neuropathy |
4 |
|
peritonitis - blood - complications - genetics |
4 |
|
phosphonic acids - therapeutic use |
4 |
|
phosphorylation |
4 |
|
polymerase inhibitor |
4 |
|
precancerous conditions - metabolism - pathology |
4 |
|
programmed cell death protein 1 |
4 |
|
propranolol |
4 |
|
protease inhibitor |
4 |
|
protein-losing enteropathies - etiology - surgery |
4 |
|
proto-oncogene proteins c-akt - antagonists & inhibitors |
4 |
|
psychometrics |
4 |
|
ranitidine - analogs & derivatives |
4 |
|
reagent kits, diagnostic |
4 |
|
real-life |
4 |
|
receptor, interferon alpha-beta - genetics |
4 |
|
receptors, interleukin-1 type i/genetics - immunology/metabolism |
4 |
|
recombinant proteins - metabolism |
4 |
|
renal toxicity |
4 |
|
retreatment |
4 |
|
reverse transcriptase inhibitors - administration & dosage |
4 |
|
rituximab |
4 |
|
rna interfering gene silencer |
4 |
|
rna, messenger - genetics - metabolism |
4 |
|
rna, messenger - metabolism |
4 |
|
rna, neoplasm |
4 |
|
rna, small interfering - metabolism |
4 |
|
rnai |
4 |
|
sars-cov-2 |
4 |
|
sc-236 |
4 |
|
sc236 cyclooxygenase-2 inhibitor |
4 |
|
screening |
4 |
|
signal transduction |
4 |
|
signal transduction - drug effects |
4 |
|
southern chinese |
4 |
|
specimen handling - instrumentation - methods - nursing |
4 |
|
stat1 |
4 |
|
stat1 transcription factor - metabolism |
4 |
|
statistics as topic |
4 |
|
stomach neoplasms - blood - diagnosis - mortality |
4 |
|
stomach neoplasms - blood - surgery |
4 |
|
stomach neoplasms - blood supply - genetics - pathology - therapy |
4 |
|
stomach neoplasms - metabolism - pathology |
4 |
|
stomach neoplasms - pathology |
4 |
|
survival |
4 |
|
systemic therapy |
4 |
|
telomerase |
4 |
|
telomerase - antagonists & inhibitors - genetics - metabolism |
4 |
|
teratogenecity |
4 |
|
thiopurine |
4 |
|
tki |
4 |
|
trans-activators - metabolism |
4 |
|
transcription initiation site |
4 |
|
transcriptional activity |
4 |
|
tretinoin - pharmacology |
4 |
|
tumor marker |
4 |
|
tumor markers, biological - analysis |
4 |
|
tumor markers, biological - metabolism |
4 |
|
tyrosine - drug effects - genetics |
4 |
|
up-regulation |
4 |
|
urea - analysis |
4 |
|
vaccine |
4 |
|
vaccines, dna - administration & dosage - immunology |
4 |
|
validity |
4 |
|
valine - genetics |
4 |
|
viral entry inhibitor |
4 |
|
viral envelope proteins - genetics |
4 |
|
viremia - complications |
4 |
|
xaf1 |
4 |
|
xenograft model antitumor assays |
4 |
|
2-pyridinylmethylsulfinylbenzimidazoles |
3 |
|
2-pyridinylmethylsulfinylbenzimidazoles - therapeutic use |
3 |
|
5-lipoxygenase |
3 |
|
absenteeism |
3 |
|
aclf |
3 |
|
acute alcoholic liver damage |
3 |
|
adenoma |
3 |
|
alpha-fetoproteins - metabolism |
3 |
|
ambulatory care facilities - utilization |
3 |
|
ambulatory surgical procedures |
3 |
|
amoxicillin - therapeutic use |
3 |
|
antacids - administration & dosage - therapeutic use |
3 |
|
anti-bacterial agents - administration & dosage - therapeutic use |
3 |
|
anti-bacterial agents - therapeutic use |
3 |
|
anti-infective agents - administration & dosage - adverse effects - pharmacology |
3 |
|
anti-infective agents - therapeutic use |
3 |
|
anti-inflammatory |
3 |
|
anti-inflammatory agents - administration & dosage - pharmacology |
3 |
|
anti-oxidative |
3 |
|
antibiotic resistance |
3 |
|
antigen |
3 |
|
antineoplastic agents - therapeutic use |
3 |
|
antirheumatic agents - toxicity |
3 |
|
antiviral agents - administration & dosage - adverse effects - pharmacokinetics - therapeutic use |
3 |
|
antiviral agents - administration and dosage |
3 |
|
anxiety |
3 |
|
apoptosis - drug effects - genetics |
3 |
|
appendicitis - complications - diagnosis |
3 |
|
arc-520 |
3 |
|
arthritis, rheumatoid - drug therapy - virology |
3 |
|
ascites |
3 |
|
aspirin - administration & dosage - pharmacology |
3 |
|
automation - instrumentation - methods |
3 |
|
bacteriophage m13 - genetics |
3 |
|
bax |
3 |
|
bcl-2-associated x protein |
3 |
|
bile duct neoplasms - complications - mortality - therapy |
3 |
|
bile ducts, intrahepatic - pathology - radiography - ultrasonography |
3 |
|
biliary tract diseases - therapy |
3 |
|
biological markers |
3 |
|
blood donors |
3 |
|
cadherins - genetics - metabolism |
3 |
|
cadherins-genetics |
3 |
|
carcinoma |
3 |
|
carcinoma, hepatocellular - drug therapy - secondary - surgery |
3 |
|
carcinoma, hepatocellular - epidemiology - virology |
3 |
|
carcinoma, hepatocellular - mortality - therapy |
3 |
|
caspases |
3 |
|
cell adhesion - genetics |
3 |
|
cell cycle - drug effects |
3 |
|
cell cycle proteins - metabolism |
3 |
|
cell division - drug effects |
3 |
|
cell proliferation |
3 |
|
cells, cultured |
3 |
|
chemoembolization, therapeutic |
3 |
|
chemoembolization, therapeutic - adverse effects - methods |
3 |
|
chemoprevention |
3 |
|
chest pain |
3 |
|
chest pain - diagnosis - etiology - psychology |
3 |
|
china - epidemiology |
3 |
|
chinese medicinal herbs |
3 |
|
cholangiocarcinoma |
3 |
|
cholangiocarcinoma - complications - mortality - therapy |
3 |
|
cholangiopancreatography, endoscopic retrograde - adverse effects - methods |
3 |
|
cholangitis - etiology |
3 |
|
cholangitis - surgery - therapy |
3 |
|
cholecystectomy - methods |
3 |
|
choledocholithiasis - complications - surgery |
3 |
|
choristoma - pathology - prevention & control |
3 |
|
chronic |
3 |
|
chronic disease |
3 |
|
chronic hepatitis b therapy |
3 |
|
chronic viral infection |
3 |
|
clarithromycin |
3 |
|
clarithromycin - administration & dosage - therapeutic use |
3 |
|
clarithromycin - therapeutic use |
3 |
|
clinical criteria for same-day discharge |
3 |
|
clinical practice |
3 |
|
colon carcinoma |
3 |
|
colorectal neoplasia |
3 |
|
comorbidity |
3 |
|
complications |
3 |
|
constipation - diagnosis |
3 |
|
constipation - epidemiology - genetics |
3 |
|
coptidis rhizoma |
3 |
|
core promoter mutations |
3 |
|
core-promoter |
3 |
|
coronary angiography |
3 |
|
cost–utility analysis |
3 |
|
creatine kinase |
3 |
|
creatine kinase - blood |
3 |
|
cyclin-dependent kinase inhibitor p27 |
3 |
|
cyclooxygenase 2 |
3 |
|
cyclooxygenase 2 inhibitors |
3 |
|
cyclooxygenase inhibitors - administration & dosage - pharmacology |
3 |
|
cyclooxygenase inhibitors - therapeutic use |
3 |
|
decompression, surgical |
3 |
|
depression |
3 |
|
dinoprostone - analysis |
3 |
|
dinoprostone - antagonists & inhibitors |
3 |
|
direct-acting antiviral agents |
3 |
|
direct-acting antivirals |
3 |
|
disease modifying drugs |
3 |
|
dna primers |
3 |
|
dna, antisense - administration & dosage - genetics |
3 |
|
dna, viral - genetics - isolation & purification |
3 |
|
double-blind method |
3 |
|
drainage |
3 |
|
drug administration schedule |
3 |
|
drug interactions |
3 |
|
drug monitoring |
3 |
|
drug resistance, bacterial |
3 |
|
drug-induced liver injury |
3 |
|
drug-induced liver injury - virology |
3 |
|
duodenal ulcer - drug therapy - microbiology - pathology |
3 |
|
dyspepsia - diagnosis |
3 |
|
efficiency |
3 |
|
elbasvir/grazoprevir |
3 |
|
end stage liver disease - etiology - therapy |
3 |
|
endoscopic retrograde cholangiopancreatography |
3 |
|
endoscopy, gastrointestinal |
3 |
|
endoscopy, gastrointestinal - utilization |
3 |
|
enoxaparin - adverse effects |
3 |
|
enzyme activation - physiology |
3 |
|
epithelial cells - pathology |
3 |
|
esophagitis - drug therapy - ethnology |
3 |
|
esophagoscopy |
3 |
|
etiology |
3 |
|
eurohep reference plasma |
3 |
|
evaluation studies as topic |
3 |
|
family characteristics |
3 |
|
family practice - organization & administration |
3 |
|
flaviviridae infections - epidemiology |
3 |
|
flow cytometry |
3 |
|
gallstones - therapy |
3 |
|
gastric acidity determination |
3 |
|
gastric mucosa - chemistry - drug effects - pathology |
3 |
|
gastritis-genetics |
3 |
|
gastro-oesophageal reflux disease |
3 |
|
gastroesophageal reflux - diagnosis - physiopathology - psychology |
3 |
|
gastroesophageal reflux disease |
3 |
|
gastrointestinal neoplasms - diagnosis |
3 |
|
gastrointestinal transit |
3 |
|
gb virus c |
3 |
|
gerbillinae |
3 |
|
granulocytic myeloid-derived suppressor cells |
3 |
|
growth inhibition |
3 |
|
guanine - adverse effects - analogs & derivatives - pharmacology - therapeutic use |
3 |
|
guideline adherence |
3 |
|
guidelines |
3 |
|
h. pylori eradication |
3 |
|
h. pylori infection |
3 |
|
hbeag seroreversion |
3 |
|
hbv dna assays |
3 |
|
hbv-dna |
3 |
|
health services accessibility - organization & administration |
3 |
|
helicobacter infections - complications - genetics - metabolism |
3 |
|
helicobacter infections - diagnosis - therapy |
3 |
|
helicobacter infections - drug therapy |
3 |
|
helicobacter infections - microbiology - pathology |
3 |
|
helicobacter pylori - isolation & purification |
3 |
|
helicobacter pylori - physiology |
3 |
|
helicobacter-infections-genetics |
3 |
|
helicobacter-pylori |
3 |
|
hemodialysis |
3 |
|
hepacivirus - classification - genetics |
3 |
|
hepacivirus - drug effects - genetics |
3 |
|
hepacivirus - genetics - isolation and purification |
3 |
|
hepacivirus - pathogenicity |
3 |
|
hepatectomy |
3 |
|
hepatic failure |
3 |
|
hepatitis - diagnosis - etiology |
3 |
|
hepatitis b - blood - diagnosis |
3 |
|
hepatitis b - complications - virology |
3 |
|
hepatitis b - prevention & control |
3 |
|
hepatitis b core antigens - immunology |
3 |
|
hepatitis b e antigens - genetics |
3 |
|
hepatitis b treatment |
3 |
|
hepatitis b vaccines - administration & dosage |
3 |
|
hepatitis b virus - drug effects - genetics - isolation & purification |
3 |
|
hepatitis b virus - drug effects - isolation & purification |
3 |
|
hepatitis b virus - genetics - isolation & purification - pathogenicity |
3 |
|
hepatitis b virus - genetics - isolation & purification - physiology |
3 |
|
hepatitis b virus - pathogenicity |
3 |
|
hepatitis b virus dna |
3 |
|
hepatitis b, chronic - blood - complications |
3 |
|
hepatitis b, chronic - blood - diagnosis |
3 |
|
hepatitis b, chronic - complications - epidemiology - genetics |
3 |
|
hepatitis b, chronic - diagnosis - drug therapy |
3 |
|
hepatitis b, chronic - diagnosis - drug therapy - immunology - virology |
3 |
|
hepatitis b, chronic - epidemiology - immunology - virology |
3 |
|
hepatitis b, chronic - virology |
3 |
|
hepatitis c - complications - virology |
3 |
|
hepatitis c - epidemiology - virology |
3 |
|
hepatitis c, chronic - complications |
3 |
|
hepatitis c, chronic - drug therapy - genetics - virology |
3 |
|
hepatitis e - immunology |
3 |
|
hepatitis e virus - immunology |
3 |
|
hepato-cellular carcinoma |
3 |
|
hepatocellular |
3 |
|
hepatoprotection |
3 |
|
heterotopic proliferative glands |
3 |
|
hiv infections - epidemiology - virology |
3 |
|
hiv-1 - classification - genetics |
3 |
|
hydrogen-ion concentration |
3 |
|
hyperplasia - prevention & control |
3 |
|
il-6 |
3 |
|
immune suppression |
3 |
|
immunocompromised host |
3 |
|
immunologic factors - therapeutic use |
3 |
|
immunosuppression |
3 |
|
indoles - pharmacology |
3 |
|
inflammation - pathology - prevention & control |
3 |
|
interferon alfa-2b - pharmacology - therapeutic use |
3 |
|
interferon-alfa |
3 |
|
interferon-alpha - administration & dosage - adverse effects |
3 |
|
interferon-α |
3 |
|
interferons |
3 |
|
interleukins - genetics - therapeutic use |
3 |
|
ischemia - chemically induced |
3 |
|
isoenzymes - antagonists & inhibitors |
3 |
|
isoenzymes - blood |
3 |
|
jnj-3989 |
3 |
|
jnk mitogen-activated protein kinases |
3 |
|
length of stay |
3 |
|
lipoxygenase inhibitors - pharmacology |
3 |
|
lithotripsy - methods |
3 |
|
liver - drug effects - enzymology - virology |
3 |
|
liver - drug effects - pathology - physiopathology |
3 |
|
liver cirrhosis |
3 |
|
liver cirrhosis - blood - complications - virology |
3 |
|
liver cirrhosis - complications - mortality - therapy |
3 |
|
liver cirrhosis, biliary - epidemiology |
3 |
|
liver diseases |
3 |
|
liver diseases - epidemiology - etiology |
3 |
|
liver diseases - etiology - pathology |
3 |
|
liver diseases, alcoholic - epidemiology |
3 |
|
liver failure, acute - etiology - therapy |
3 |
|
liver neoplasms |
3 |
|
liver neoplasms - drug therapy - pathology - surgery |
3 |
|
liver neoplasms - mortality - therapy |
3 |
|
lung metastasis |
3 |
|
lung neoplasms - drug therapy - secondary - surgery |
3 |
|
manometry |
3 |
|
mass screening |
3 |
|
median survival |
3 |
|
medical therapy |
3 |
|
membrane proteins |
3 |
|
metastasis |
3 |
|
methylation |
3 |
|
metronidazole - administration & dosage - therapeutic use |
3 |
|
metronidazole - therapeutic use |
3 |
|
microbial sensitivity tests |
3 |
|
mitogen-activated protein kinases - antagonists & inhibitors |
3 |
|
mk-886 |
3 |
|
model of end-stage liver disease |
3 |
|
monitor |
3 |
|
multicenter studies as topic - statistics & numerical data |
3 |
|
muscular diseases - blood - chemically induced |
3 |
|
mutants |
3 |
|
myrcludex b |
3 |
|
nadroparin - adverse effects |
3 |
|
nonalcoholic fatty liver disease |
3 |
|
nucleocapsids |
3 |
|
nucleosides - administration & dosage - adverse effects - pharmacokinetics - therapeutic use |
3 |
|
ocular complication |
3 |
|
oesophagitis |
3 |
|
oligodeoxyribonucleotides |
3 |
|
omeprazole - administration & dosage - adverse effects - analogs & derivatives - pharmacology |
3 |
|
omeprazole - therapeutic use |
3 |
|
open-access |
3 |
|
organometallic compounds - therapeutic use |
3 |
|
outcome |
3 |
|
outcome and process assessment (health care) |
3 |
|
outpatient |
3 |
|
pancreatitis - etiology - prevention & control |
3 |
|
pathogenesis |
3 |
|
patient readmission |
3 |
|
pedigree |
3 |
|
peripheral nervous system diseases - chemically induced |
3 |
|
peritoneal dialysis |
3 |
|
ph monitoring |
3 |
|
phosphonic acids - adverse effects - pharmacology - therapeutic use |
3 |
|
phosphorylation - drug effects |
3 |
|
physician's practice patterns |
3 |
|
pilot projects |
3 |
|
plasmids |
3 |
|
platelet count |
3 |
|
pneumonectomy |
3 |
|
portal vein thrombosis |
3 |
|
post-therapeutic complication |
3 |
|
postoperative complications |
3 |
|
pre-core |
3 |
|
precore mutations |
3 |
|
pregnancy |
3 |
|
pregnancy complications, infectious - drug therapy |
3 |
|
primary biliary cirrhosis |
3 |
|
professional practice |
3 |
|
promoter-regions-genetics-genetics |
3 |
|
prostaglandin-endoperoxide synthases |
3 |
|
protein kinase c - antagonists & inhibitors - genetics |
3 |
|
protein kinase c-alpha |
3 |
|
prothrombin time |
3 |
|
proto-oncogene proteins - metabolism |
3 |
|
proto-oncogene proteins c-bcl-2 |
3 |
|
proton pump inhibitors |
3 |
|
psychiatric status rating scales |
3 |
|
pulmonary embolism - drug therapy |
3 |
|
pyrazoles - administration & dosage - pharmacology |
3 |
|
pyrazoles - therapeutic use |
3 |
|
pyrimidinones - administration & dosage - adverse effects - pharmacokinetics - therapeutic use |
3 |
|
quantification |
3 |
|
randomized controlled trials as topic |
3 |
|
referral and consultation - organization & administration |
3 |
|
reishi |
3 |
|
renal replacement therapy |
3 |
|
renal transplantation |
3 |
|
retina |
3 |
|
retinal vessels - drug effects |
3 |
|
review |
3 |
|
ribavirin - pharmacology - therapeutic use |
3 |
|
serum albumin |
3 |
|
sick leave |
3 |
|
social behavior |
3 |
|
sphincterotomy, endoscopic |
3 |
|
sphincterotomy, endoscopic - methods |
3 |
|
steatosis |
3 |
|
stents |
3 |
|
stents - adverse effects |
3 |
|
stomach neoplasms - enzymology - genetics - pathology - therapy |
3 |
|
stomach neoplasms - genetics - metabolism - microbiology |
3 |
|
stomach neoplasms - immunology |
3 |
|
subviral particles |
3 |
|
sulfonamides - administration & dosage - pharmacology |
3 |
|
sulfonamides - therapeutic use |
3 |
|
survey |
3 |
|
systemic interferon |
3 |
|
tetradecanoylphorbol acetate - pharmacology |
3 |
|
tomography, x-ray computed |
3 |
|
transcription factor ap-1 - antagonists & inhibitors |
3 |
|
treatment cessation |
3 |
|
tumor response |
3 |
|
tumor suppressor proteins - metabolism |
3 |
|
ultrasonography, doppler |
3 |
|
unresectable hepatocellular carcinoma |
3 |
|
upper endoscopy |
3 |
|
viral proteins - physiology |
3 |
|
viremia - epidemiology - virology |
3 |
|
virulence factors - physiology |
3 |
|
waiting lists |
3 |
|
yap |
3 |
|
2-aminopurine - adverse effects - analogs & derivatives - therapeutic use |
2 |
|
acute decompensation |
2 |
|
acute hepatic decompensation |
2 |
|
acute hepatitis |
2 |
|
acute kidney injury |
2 |
|
acute liver failure and scute liver failure |
2 |
|
acute on chronic liver failure |
2 |
|
acute-on-chronicliver disease |
2 |
|
adefovir dipivoxil |
2 |
|
adenine - adverse effects - analogs & derivatives - therapeutic use |
2 |
|
adenine - analogs & derivatives - pharmacokinetics - therapeutic use |
2 |
|
adenine - analogs & derivatives - pharmacology |
2 |
|
adenine - analogs & derivatives - pharmacology - therapeutic use |
2 |
|
adenocarcinoma - epidemiology |
2 |
|
adjuvants, immunologic - pharmacology - therapeutic use |
2 |
|
adrenal cortex hormones - adverse effects - therapeutic use |
2 |
|
albumins - analysis |
2 |
|
alpha-fetoprotein |
2 |
|
alt normalization |
2 |
|
amino acid substitution |
2 |
|
ampulla of vater - surgery |
2 |
|
angiography |
2 |
|
anti-bacterial agents |
2 |
|
anti-bacterial agents - administration & dosage |
2 |
|
anti-bacterial agents - adverse effects - therapeutic use |
2 |
|
anti-infective agents - administration & dosage |
2 |
|
anti-inflammatory agents, non-steroidal - administration & dosage - adverse effects |
2 |
|
anti-ulcer agents - administration & dosage |
2 |
|
anti-ulcer agents - adverse effects - therapeutic use |
2 |
|
antibodies, bacterial - urine |
2 |
|
antibodies, viral - analysis |
2 |
|
antidepressive agents, tricyclic - adverse effects |
2 |
|
antigenemia |
2 |
|
antigens, bacterial - isolation & purification |
2 |
|
antineoplastic agents, hormonal - therapeutic use |
2 |
|
antitubercular agents - adverse effects |
2 |
|
antiviral agents |
2 |
|
antiviral agents - administration & dosage - therapeutic use |
2 |
|
antiviral agents - chemistry - pharmacology - therapeutic use |
2 |
|
antiviral agents - chemistry - therapeutic use |
2 |
|
antiviral agents - pharmacokinetics - therapeutic use |
2 |
|
antivirals |
2 |
|
asia - epidemiology |
2 |
|
asia pacific |
2 |
|
asia, southeastern |
2 |
|
aspirin - administration & dosage - adverse effects |
2 |
|
asthma |
2 |
|
bare metal stent |
2 |
|
barrett esophagus - epidemiology |
2 |
|
benzimidazoles - administration & dosage |
2 |
|
benzimidazoles - adverse effects - therapeutic use |
2 |
|
bismuth - adverse effects - therapeutic use |
2 |
|
carcinoma, hepatocellular - diagnosis - economics - pathology |
2 |
|
carcinoma, hepatocellular - diagnosis - physiopathology - therapy - ultrasonography |
2 |
|
carcinoma, hepatocellular - drug therapy |
2 |
|
carcinoma, hepatocellular - etiology - genetics |
2 |
|
carcinoma, hepatocellular - genetics - physiopathology |
2 |
|
carcinoma, hepatocellular - mortality |
2 |
|
carcinoma, hepatocellular - mortality - prevention & control - therapy - virology |
2 |
|
carcinoma, hepatocellular - prevention and control |
2 |
|
carcinoma, hepatocellular - prevention and control - virology |
2 |
|
carcinoma, hepatocellular - therapy |
2 |
|
carcinoma, squamous cell - epidemiology |
2 |
|
carrier state - drug therapy |
2 |
|
catheterization |
2 |
|
cause of death |
2 |
|
cell cycle |
2 |
|
cell transformation, neoplastic |
2 |
|
chb |
2 |
|
cholangitis - diagnosis - physiopathology - surgery |
2 |
|
cholangitis - prevention & control |
2 |
|
cholangitis - surgery |
2 |
|
cholecystectomy |
2 |
|
cholelithiasis - complications |
2 |
|
chronic hepatitis b infection |
2 |
|
chronic hepatitis b, ymdd hbv variant |
2 |
|
chronic hepatitis c infection |
2 |
|
chronic obstructive pulmonary disease |
2 |
|
clinical trials as topic |
2 |
|
clinical trials, phase i as topic |
2 |
|
clinical trials, phase ii as topic |
2 |
|
cohort |
2 |
|
colonic neoplasms - diagnosis |
2 |
|
colonoscopy |
2 |
|
colonoscopy - utilization |
2 |
|
colonoscopy screening |
2 |
|
colorectal cancer |
2 |
|
colorectal malignant neoplasm |
2 |
|
colorectal neoplasms - epidemiology |
2 |
|
communicable diseases |
2 |
|
contrast media - administration & dosage - therapeutic use |
2 |
|
core inhibitor |
2 |
|
core promoter |
2 |
|
cost-benefit analysis |
2 |
|
cost-effectiveness |
2 |
|
costs and cost analysis |
2 |
|
cross-linking reagents |
2 |
|
des-gamma-carboxyprothrombin |
2 |
|
diarrhea - chemically induced |
2 |
|
dimensioning |
2 |
|
disease burden |
2 |
|
dna probes |
2 |
|
dna, viral - analysis - drug effects |
2 |
|
dna, viral - analysis - metabolism |
2 |
|
duodenal ulcer - drug therapy - microbiology |
2 |
|
duodenal ulcer - prevention & control |
2 |
|
dyspepsia - complications - drug therapy - microbiology |
2 |
|
dyspepsia - drug therapy - microbiology |
2 |
|
dyspepsia - epidemiology - microbiology |
2 |
|
endoscopy, digestive system |
2 |
|
enhancer elements, genetic |
2 |
|
enhancer ii |
2 |
|
esophageal neoplasms - epidemiology |
2 |
|
esophageal stenosis - epidemiology |
2 |
|
esophagitis - epidemiology - microbiology |
2 |
|
estrogen receptor α |
2 |
|
europe - epidemiology |
2 |
|
european continental ancestry group |
2 |
|
evolution, molecular |
2 |
|
exanthema - chemically induced |
2 |
|
famciclovir |
2 |
|
feces - microbiology |
2 |
|
fibrosis - etiology - prevention & control |
2 |
|
fibrosis - pathology |
2 |
|
forecasting |
2 |
|
gastric mucosa - metabolism - pathology |
2 |
|
genes, fos - genetics |
2 |
|
genes, jun - genetics |
2 |
|
genes, myc - genetics |
2 |
|
genome, viral - genetics |
2 |
|
ggt |
2 |
|
glecaprevir and pibrentasvir |
2 |
|
globe trial |
2 |
|
glypican-3 |
2 |
|
glypicans |
2 |
|
golden window |
2 |
|
guanine - administration & dosage - adverse effects - analogs & derivatives - pharmacokinetics - therapeutic use |
2 |
|
guanine - adverse effects - analogs & derivatives - therapeutic use |
2 |
|
guanine - analogs and derivatives - pharmacology - therapeutic use |
2 |
|
hbeag loss |
2 |
|
hbeag negative |
2 |
|
hbeag positive |
2 |
|
hbeag serconversion |
2 |
|
hbsag loss |
2 |
|
hbv dna levels |
2 |
|
hbv genotype ba, bj, c |
2 |
|
health behavior |
2 |
|
health services needs and demand |
2 |
|
heart rate |
2 |
|
helicobacter infections - complications |
2 |
|
helicobacter infections - complications - epidemiology |
2 |
|
helicobacter infections - diagnosis - ethnology |
2 |
|
helicobacter infections - drug therapy - ethnology |
2 |
|
helicobacter infections - drug therapy - metabolism - pathology |
2 |
|
helicobacter infections - drug therapy - microbiology |
2 |
|
helicobacter infections - urine |
2 |
|
helicobacter pylori - drug effects |
2 |
|
helicobacter pylori - drug effects - isolation & purification |
2 |
|
helicobacter pylori - enzymology - immunology |
2 |
|
helicobacter pylori - immunology |
2 |
|
hepacivirus - classification - isolation & purification |
2 |
|
hepacivirus - drug effects |
2 |
|
hepacivirus - genetics - isolation & purification |
2 |
|
hepacivirus - immunology |
2 |
|
hepatitis b - blood - drug therapy - prevention & control |
2 |
|
hepatitis b - chemically induced - immunology - virology |
2 |
|
hepatitis b - complications - mortality - prevention & control |
2 |
|
hepatitis b - drug therapy - epidemiology - virology |
2 |
|
hepatitis b - enzymology - ethnology - immunology - physiopathology |
2 |
|
hepatitis b - prevention & control - therapy - transmission |
2 |
|
hepatitis b antibodies - analysis |
2 |
|
hepatitis b antibodies - immunology |
2 |
|
hepatitis b e antigens - analysis |
2 |
|
hepatitis b e antigens - blood - immunology |
2 |
|
hepatitis b e antigens - immunology |
2 |
|
hepatitis b reactivation |
2 |
|
hepatitis b surface antigens - analysis |
2 |
|
hepatitis b vaccines |
2 |
|
hepatitis b vaccines - administration & dosage - therapeutic use |
2 |
|
hepatitis b vaccines - therapeutic use |
2 |
|
hepatitis b virus - classification - drug effects - genetics |
2 |
|
hepatitis b virus - drug effects - genetics - physiology |
2 |
|
hepatitis b virus - drug effects - isolation & purification - physiology |
2 |
|
hepatitis b virus - drug effects - physiology |
2 |
|
hepatitis b virus - genetics - immunology - pathogenicity |
2 |
|
hepatitis b virus - genetics - pathogenicity |
2 |
|
hepatitis b virus - metabolism |
2 |
|
hepatitis b, chronic - blood - drug therapy - enzymology - virology |
2 |
|
hepatitis b, chronic - complications - diagnosis - drug therapy |
2 |
|
hepatitis b, chronic - complications - immunology - virology |
2 |
|
hepatitis b, chronic - drug therapy - economics |
2 |
|
hepatitis b, chronic - drug therapy - epidemiology - immunology - virology |
2 |
|
hepatitis b, chronic - drug therapy - epidemiology - virology |
2 |
|
hepatitis b, chronic - drug therapy - immunology |
2 |
|
hepatitis b, chronic - genetics - virology |
2 |
|
hepatitis b, chronic - immunology - pathology - virology |
2 |
|
hepatitis c - complications - epidemiology - virology |
2 |
|
hepatitis c - complications - mortality - prevention & control |
2 |
|
hepatitis c - drug therapy - pathology - virology |
2 |
|
hepatitis c, chronic - complications - epidemiology |
2 |
|
hepatocellular carcinoma (hcc) |
2 |
|
historical |
2 |
|
hiv infections - drug therapy - epidemiology |
2 |
|
immunoassay |
2 |
|
immunochemistry |
2 |
|
immunochromatography |
2 |
|
in-stent restenosis |
2 |
|
india |
2 |
|
infectious disease |
2 |
|
infusions, intra-arterial |
2 |
|
interferon |
2 |
|
interferon α |
2 |
|
interferon-alpha - administration & dosage - therapeutic use |
2 |
|
interferon-alpha - adverse effects - pharmacology - therapeutic use |
2 |
|
interferon-alpha - pharmacology - therapeutic use |
2 |
|
intervention studies |
2 |
|
iodized oil - administration & dosage - therapeutic use |
2 |
|
kidney diseases - chemically induced |
2 |
|
liver - pathology - physiopathology |
2 |
|
liver - physiopathology |
2 |
|
liver cirrhosis - chemically induced - physiopathology |
2 |
|
liver diseases - pathology - physiopathology |
2 |
|
liver imaging |
2 |
|
liver neoplasms - diagnosis |
2 |
|
liver neoplasms - diagnosis - economics - pathology |
2 |
|
liver neoplasms - diagnosis - physiopathology - therapy - ultrasonography |
2 |
|
liver neoplasms - drug therapy |
2 |
|
liver neoplasms - etiology - genetics |
2 |
|
liver neoplasms - genetics - physiopathology |
2 |
|
liver neoplasms - mortality |
2 |
|
liver neoplasms - mortality - prevention & control - therapy - virology |
2 |
|
liver neoplasms - prevention and control |
2 |
|
liver neoplasms - prevention and control - virology |
2 |
|
liver neoplasms - therapy |
2 |
|
liver transplantation - adverse effects - methods |
2 |
|
mass screening - economics |
2 |
|
medicine |
2 |
|
membrane proteins - blood |
2 |
|
mental health |
2 |
|
metronidazole |
2 |
|
mianserin - adverse effects - analogs & derivatives |
2 |
|
mir-130a |
2 |
|
mirtazapine |
2 |
|
molecular structure |
2 |
|
multiple organ failure |
2 |
|
mutation, missense |
2 |
|
na |
2 |
|
neoplasm |
2 |
|
neoplasm proteins - blood |
2 |
|
nonalcoholic steatohepatitis |
2 |
|
nucleic acid hybridization - methods |
2 |
|
nucleoside analogs |
2 |
|
nucleosides - chemistry - pharmacology - therapeutic use |
2 |
|
nucleotides - administration & dosage - adverse effects - chemistry - pharmacokinetics |
2 |
|
occult blood |
2 |
|
octreotide - therapeutic use |
2 |
|
ofloxacin - administration & dosage |
2 |
|
omeprazole - adverse effects - analogs & derivatives - therapeutic use |
2 |
|
omeprazole - adverse effects - therapeutic use |
2 |
|
omeprazole - analogs & derivatives |
2 |
|
organ failure |
2 |
|
palliative care |
2 |
|
pathology |
2 |
|
patient compliance |
2 |
|
patient education as topic |
2 |
|
pegylated interferon/ribavirin |
2 |
|
penicillins - therapeutic use |
2 |
|
peptic ulcer - epidemiology - microbiology |
2 |
|
phenotype |
2 |
|
phosphonic acids |
2 |
|
phosphonic acids - administration & dosage - adverse effects - pharmacokinetics - therapeutic use |
2 |
|
phosphonic acids - adverse effects - therapeutic use |
2 |
|
phosphonic acids - pharmacokinetics - therapeutic use |
2 |
|
phosphonic acids - pharmacology |
2 |
|
physical functioning |
2 |
|
piro |
2 |
|
plant lectins |
2 |
|
plasma |
2 |
|
point mutation |
2 |
|
polymerase chain reaction |
2 |
|
postoperative hemorrhage - chemically induced - prevention & control |
2 |
|
practice guidelines as topic - standards |
2 |
|
precore genome |
2 |
|
prodrugs - administration & dosage - adverse effects - metabolism - pharmacokinetics |
2 |
|
proliferation |
2 |
|
prolonged jaundice |
2 |
|
protein precursors - blood |
2 |
|
prothrombin |
2 |
|
proton-translocating atpases - antagonists & inhibitors |
2 |
|
public health |
2 |
|
pyloric antrum - metabolism - pathology |
2 |
|
pyrimidinones - chemistry - pharmacology - therapeutic use |
2 |
|
radiology |
2 |
|
ranitidine - adverse effects - analogs & derivatives - therapeutic use |
2 |
|
rapid stool test |
2 |
|
real-b |
2 |
|
recurrence - prevention & control |
2 |
|
regression analysis |
2 |
|
renal insufficiency |
2 |
|
research design |
2 |
|
resistant mutation |
2 |
|
resource implication |
2 |
|
reverse transcriptase inhibitors - pharmacology - therapeutic use |
2 |
|
ribavirin - administration & dosage - therapeutic use |
2 |
|
rifabutin - administration & dosage |
2 |
|
risk prediction |
2 |
|
rna, viral - genetics |
2 |
|
scale-b |
2 |
|
sequence analysis, dna |
2 |
|
seroconversion |
2 |
|
serologic tests - methods - standards |
2 |
|
serological marker |
2 |
|
single nucleotides polymorphisms |
2 |
|
sirs |
2 |
|
societies, medical |
2 |
|
sofosbuvir |
2 |
|
species specificity |
2 |
|
stomach ulcer - prevention & control |
2 |
|
subgenotype c |
2 |
|
subgenotypes |
2 |
|
surgical procedures, elective |
2 |
|
surveillance |
2 |
|
sustained response |
2 |
|
sustained virological response |
2 |
|
systemic corticosteroid |
2 |
|
t-cell exhaustion |
2 |
|
tdf |
2 |
|
tolerancing |
2 |
|
transcatheter intraarterial lipiodol chemoembolization (tace) |
2 |
|
tyrosine-methionine-aspartate-aspartate (ymdd) mutations |
2 |
|
ultrasonography |
2 |
|
ultrasonography - economics |
2 |
|
united states - epidemiology |
2 |
|
urease - metabolism |
2 |
|
vaccines, dna - administration & dosage - therapeutic use |
2 |
|
variational geometry |
2 |
|
viral resistance |
2 |
|
virus activation - drug effects |
2 |
|
virus replication - drug effects |
2 |
|
vitality |
2 |
|
yeasts |
2 |
|
ymdd mutants |
2 |
|
α-fetoprotein |
2 |
|
aarc |
1 |
|
activins - blood |
1 |
|
acute variceal bleeding |
1 |
|
alanine aminotransferase level |
1 |
|
alcoholic hepatitis |
1 |
|
alf |
1 |
|
alp |
1 |
|
alpha fetoprotein |
1 |
|
anti-viral agents |
1 |
|
antibiotics |
1 |
|
antigens, cd3 - immunology |
1 |
|
antigens, cd56 - immunology |
1 |
|
antigens, cd95 - blood - metabolism |
1 |
|
antiviral agents - administration & dosage |
1 |
|
azathioprine - administration & dosage - adverse effects |
1 |
|
b-lymphocyte subsets - immunology - pathology |
1 |
|
bmi |
1 |
|
candidate snp |
1 |
|
capsid assembly modulator |
1 |
|
carcinoma, hepatocellular - blood |
1 |
|
carcinoma, hepatocellular - diagnosis - economics - epidemiology |
1 |
|
carcinoma, hepatocellular - epidemiology - ethnology - etiology - mortality - therapy |
1 |
|
carcinoma, hepatocellular - immunology |
1 |
|
carcinoma, hepatocellular - immunology - pathology |
1 |
|
carcinoma, hepatocellular - prevention & control - virology |
1 |
|
cd4-positive t-lymphocytes - immunology |
1 |
|
cd8-positive t-lymphocytes - immunology |
1 |
|
cholangiopancreatography, endoscopic retrograde - adverse effects |
1 |
|
cholelithiasis - therapy |
1 |
|
chronic hepatitis b (chb) |
1 |
|
clinical implication |
1 |
|
clinical trial |
1 |
|
consensus |
1 |
|
core protein inhibitor |
1 |
|
crohn disease - complications - drug therapy |
1 |
|
crohn's disease |
1 |
|
dendritic |
1 |
|
developing nation |
1 |
|
diagnostic test |
1 |
|
direct-acting antiviral |
1 |
|
effectiveness |
1 |
|
elimination |
1 |
|
encapsidation |
1 |
|
end stage liver disease |
1 |
|
ethnicity |
1 |
|
finite therapy |
1 |
|
follistatin |
1 |
|
gastrectomy - methods |
1 |
|
gene expression |
1 |
|
genome-wide association study |
1 |
|
graft survival |
1 |
|
hbsag reduction |
1 |
|
hbv biomarkers |
1 |
|
hbv cccdna |
1 |
|
hbv dna suppression |
1 |
|
hbv s variants |
1 |
|
hbv surface antigen |
1 |
|
hbv transmission |
1 |
|
hbv vaccine |
1 |
|
hemophilia |
1 |
|
hemophilia a - complications - virology |
1 |
|
hepacivirus - drug effects - genetics - isolation & purification |
1 |
|
hepatic venous pressure gradient |
1 |
|
hepatitis b - surgery |
1 |
|
hepatitis b reativation |
1 |
|
hepatitis b virus (hbv) |
1 |
|
hepatitis b, chronic - blood - complications - immunology - virology |
1 |
|
hepatitis b, chronic - complications - diagnosis - drug therapy - prevention & control |
1 |
|
hepatitis c - diagnosis - drug therapy - epidemiology |
1 |
|
hepatitis c - drug therapy - etiology |
1 |
|
hepatitis c, chronic - diagnosis - drug therapy - epidemiology |
1 |
|
hiv |
1 |
|
hiv seropositivity |
1 |
|
immune clearance |
1 |
|
immunization programs |
1 |
|
inarigivir |
1 |
|
inequality |
1 |
|
infant, newborn |
1 |
|
infection |
1 |
|
infections |
1 |
|
interferon alfa |
1 |
|
interferon-alpha - administration & dosage |
1 |
|
interferons - pharmacology - therapeutic use |
1 |
|
interferons - therapeutic use |
1 |
|
killer cells, natural - immunology |
1 |
|
killer cells, natural - immunology - pathology |
1 |
|
killer inhibitory receptor |
1 |
|
lamivudine-resistant |
1 |
|
linvencorvir |
1 |
|
liver cancer immunology |
1 |
|
liver cirrhosis - diagnosis - pathology |
1 |
|
liver cirrhosis - prevention & control - virology |
1 |
|
liver cirrhosis, alcoholic - blood |
1 |
|
liver neoplasms - blood |
1 |
|
liver neoplasms - diagnosis - economics - epidemiology |
1 |
|
liver neoplasms - epidemiology - ethnology - etiology - mortality - therapy |
1 |
|
liver neoplasms - immunology |
1 |
|
liver neoplasms - immunology - pathology |
1 |
|
liver neoplasms - prevention & control - virology |
1 |
|
lymphocytes, tumor-infiltrating - immunology - pathology |
1 |
|
mortality and etiology |
1 |
|
multi-center |
1 |
|
myelodysplasia |
1 |
|
myelodysplastic syndromes - etiology - genetics |
1 |
|
natural killer cell |
1 |
|
natural t cell |
1 |
|
neutrophil function |
1 |
|
neutrophils - immunology |
1 |
|
new combination therapy |
1 |
|
nucleos(t)ide reverse transcriptase inhibitor |
1 |
|
nucleoside/nucleotide analog |
1 |
|
obi |
1 |
|
occult hbv infection |
1 |
|
odds ratio |
1 |
|
off-treatment |
1 |
|
open-label |
1 |
|
patients |
1 |
|
pharmacology |
1 |
|
phase 1 study |
1 |
|
phase 2 |
1 |
|
pneumothorax - etiology |
1 |
|
polyethylene glycols - pharmacology - therapeutic use |
1 |
|
population surveillance - methods |
1 |
|
portal hypertension |
1 |
|
portal pressure |
1 |
|
prognostic scores |
1 |
|
real world |
1 |
|
real-world |
1 |
|
rebleeding |
1 |
|
receptors, immunologic - biosynthesis - immunology |
1 |
|
receptors, kir |
1 |
|
receptors, kir2dl3 |
1 |
|
replication study |
1 |
|
retinoic acid-inducible gene 1 |
1 |
|
ribavirin - administration & dosage |
1 |
|
rna, viral - analysis - genetics - immunology |
1 |
|
ro7049389 |
1 |
|
scenarios |
1 |
|
sepsis |
1 |
|
septic shock |
1 |
|
serotyping |
1 |
|
short interfering rna |
1 |
|
side effects |
1 |
|
sirna |
1 |
|
soluble fibrinogen-like protein 2 |
1 |
|
stopping finite therapy |
1 |
|
strategy |
1 |
|
sulfasalazine |
1 |
|
sulfasalazine - administration & dosage |
1 |
|
surveillance for hcc |
1 |
|
t-lymphocytes, cytotoxic - immunology |
1 |
|
therapeutic use |
1 |
|
tolerability |
1 |
|
transforming growth factor beta - blood |
1 |
|
transforming growth factor β |
1 |
|
treatment discontinuation |
1 |
|
trisomy |
1 |
|
tumor-infiltrating lymphocytes |
1 |
|
tumour size |
1 |
|
ultrasound |
1 |
|
undertreatment |
1 |
|
universal precaution |
1 |
|
viral relapse |
1 |
